diethyl spiro[3.3]heptane-2,6-dicarboxylate | 142292-56-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: diethyl spiro[3.3]heptane-2,6-dicarboxylate
• CAS: 142292-56-6
• 化学式: C₁₃H₂₀O₄
• 分子量: 240.299
• InChiKey: GNJWXXQQMIJNDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  diethyl spiro[3.3]heptane-2,6-dicarboxylate 生成 spiro[3.3]heptane-2,6-dicarboxylic acid
  参考文献：
  名称：

  NAEMURA, KOICHIRO;FURUTANI, ATSUSHI, J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N1, C. 3215-3217

  摘要：

  DOI：
• 作为产物：
  描述：

  乙醇 、 spiro[3.3]heptane-2,6-dicarboxylic acid 在 硫酸 作用下， 以 苯 为溶剂， 反应 3.5h， 以76%的产率得到diethyl spiro[3.3]heptane-2,6-dicarboxylate
  参考文献：
  名称：

  Naemura, Koichiro; Furutani, Atsushi, Journal of Chemical Research, Miniprint, 1992, # 6, p. 1301 - 1326

  摘要：

  DOI：

文献信息

• [EN] CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] COMPOSÉS MONO ET SPIROCYCLIQUES CONTENANT DU CYCLOBUTANE ET DE L'AZÉTIDINE EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA V
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018089355A1

  公开（公告）日：2018-05-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是αv-含有整合素的拮抗剂。本发明还涉及包括这些化合物的药物组合物以及利用这些化合物和药物组合物治疗与αv-含有整合素失调相关的疾病、紊乱或病况的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• [EN] ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS<br/>[FR] COMPOSÉS SPIROCYCLIQUES D'ALCÈNE EN TANT QUE MODULATEURS DU RÉCEPTEUR FARNÉSOÏDE X
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019089665A1

  公开（公告）日：2019-05-09

  The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（I）的化合物，或其立体异构体、互变异构体、或其药学上可接受的盐或溶剂，其中所有变量均如本文所定义。这些化合物调节法尼索酮X受体（FXR）的活性，例如作为激动剂。该发明还涉及包含这些化合物的药物组合物以及使用这些化合物和药物组合物来治疗与FXR失调相关的疾病、紊乱或病况，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病的方法。
• Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11014922B2

  公开（公告）日：2021-05-25

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式（I）化合物：或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量如本文所定义。这些化合物是含αv整合素的拮抗剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与含av整合素失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• Alkene spirocyclic compounds as farnesoid X receptor modulators
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US11286252B2

  公开（公告）日：2022-03-29

  The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

  本发明提供了式(I)化合物或其立体异构体、同系物或药学上可接受的盐或溶液，其中所有变量如本文所定义。这些化合物可调节类法尼醇 X 受体 (FXR) 的活性，例如作为激动剂。本发明还涉及包含这些化合物的药物组合物，以及通过使用这些化合物和药物组合物治疗与 FXR 失调相关的疾病、紊乱或病症的方法，如病理性纤维化、移植排斥、癌症、骨质疏松症和炎症性疾病。
• NAEMURA, KOICHIRO;FURUTANI, ATSUSHI, J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N1, C. 3215-3217
  作者：NAEMURA, KOICHIRO、FURUTANI, ATSUSHI

  DOI：——

  日期：——